travellinglight/iStock via Getty Images
Cassava Sciences (NASDAQ:SAVA) lost ~19% in the premarket on Tuesday after the company announced plans to discontinue its research program for its lead asset simufilam in Alzheimer’s disease by the end of the second quarter following a failure